广州安必平医药科技股份有限公司 2025 年第二次临时股东大会会议资料 会议资料 2025 年 11 月 广州安必平医药科技股份有限公司 2025 年第二次临时股东大会会议资料 公司代码：688393 公司简称：安必平 广州安必平医药科技股份有限公司 2025 年第二次临时股东大会 目录 | 2025 | 年第二次临时股东大会会议须知 | 2 | | --- | --- | --- | | 2025 | 年第二次临时股东大会会议议程 | 4 | | 2025 | 年第二次临时股东大会会议议案 | 6 | | | 议案一 关于撤销监事会暨废止《监事会议事规则》的议案 | 6 | | | 议案二 关于修订《公司章程》并办理工商变更登记的议案 | 7 | | | 议案三 关于修订《股东大会议事规则》等内部治理制度，制定《董事、高 | | | | 级管理人员薪酬管理制度》的议案 8 | | 1 广州安必平医药科技股份有限公司 2025 年第二次临时股东大会会议资料 2025 年第二次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》《 ...

Core Insights - The internet healthcare sector experienced a slight increase of 0.21% on October 29, with notable gains from companies like Jiangyu Pingmin, which rose by 6.29% [1] - The Shanghai Composite Index closed at 4016.33, up 0.7%, while the Shenzhen Component Index closed at 13691.38, up 1.95% [1] Company Performance - Jiangyu Pingmin (301017) closed at 11.99 with a gain of 6.29%, trading volume of 201,100 shares and a transaction value of 242 million [1] - Furuishi (300049) closed at 74.48, up 6.20%, with a trading volume of 150,500 shares and a transaction value of 1.104 billion [1] - Xingqi Eye Medicine (300573) closed at 82.01, increasing by 5.29%, with a trading volume of 309,400 shares and a transaction value of 2.518 billion [1] - Other notable performers include Maidi Technology (603990) with a 2.98% increase and a transaction value of 384 million, and Hanhui Technology (300007) with a 2.68% increase and a transaction value of 1.402 billion [1] Market Dynamics - The internet healthcare sector saw a net outflow of 1.125 billion from institutional investors, while retail investors contributed a net inflow of 926 million [2][3] - The overall market sentiment indicated a mixed response, with some stocks experiencing significant declines, such as Jiayuan Technology (301117) which fell by 13.29% [2] - The trading activity highlighted a divergence in investor behavior, with institutional investors pulling back while retail investors remained active [2][3]

Core Viewpoint - Anbiping experienced a decline of 5.14% in stock price, closing at 24.34 CNY per share, with a total market capitalization of 2.277 billion CNY [1] Company Overview - Guangzhou Anbiping Medical Technology Co., Ltd. was established on July 6, 2005, and went public on August 20, 2020. The company specializes in the research, production, and sales of in vitro diagnostic reagents and instruments [1] - The revenue composition of the company includes: self-produced products (79.72%), purchased products (13.11%), service income (5.90%), and other (1.27%) [1] Shareholder Information - Changcheng Fund's Changcheng Consumption Value Mixed A (200006) is among the top ten circulating shareholders of Anbiping, holding 850,000 shares, which represents 0.91% of the circulating shares [2] - The fund has not changed its shareholding compared to the previous period, and the estimated floating loss today is approximately 1.122 million CNY [2] Fund Manager Profile - The fund manager of Changcheng Consumption Value Mixed A is Long Yufei, who has been in the position for 8 years and 14 days. The total asset size of the fund is 843 million CNY [3] - During Long Yufei's tenure, the best fund return was 61.42%, while the worst return was -8.9% [3]

Core Viewpoint - Anbiping's stock price has experienced fluctuations, with a year-to-date increase of 45.96% but a recent decline in the last few trading days, indicating potential volatility in investor sentiment [2]. Group 1: Stock Performance - As of October 29, Anbiping's stock price was 25.12 CNY per share, down 2.10% during the trading session, with a total market capitalization of 2.35 billion CNY [1]. - Year-to-date, Anbiping's stock has risen by 45.96%, but it has seen a decline of 2.60% over the last five trading days, 4.05% over the last 20 days, and 20.08% over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Anbiping reported revenue of 253 million CNY, a year-on-year decrease of 28.29%, and a net profit attributable to shareholders of -10.77 million CNY, a decrease of 136.34% [2]. - Cumulative cash dividends since the A-share listing amount to 87.80 million CNY, with 36.46 million CNY distributed over the last three years [3]. Group 3: Shareholder Information - As of September 30, 2025, Anbiping had 7,567 shareholders, a decrease of 17.94% from the previous period, with an average of 12,365 circulating shares per shareholder, an increase of 21.86% [2]. - The eighth largest circulating shareholder is Changcheng Consumption Value Mixed A, holding 850,000 shares, with no change in the number of shares held compared to the previous period [3]. Group 4: Company Overview - Anbiping, established on July 6, 2005, and listed on August 20, 2020, is based in Guangzhou, Guangdong Province, and specializes in the research, production, and sales of in vitro diagnostic reagents and instruments [2]. - The company's main business revenue composition includes 79.72% from self-produced products, 13.11% from purchased products, 5.90% from service income, and 1.27% from other sources [2].

Summary of the Conference Call for Anbiping Company Overview - **Company**: Anbiping - **Industry**: Medical diagnostics, specifically focusing on HPV products, AI in healthcare, and pathology services Key Financial Performance - **Revenue**: Third quarter revenue decreased by 24.95% year-on-year, totaling 253 million RMB, with a total profit loss of 1,741 million RMB, a decline of 187% [2][3] - **Net Profit**: Net profit attributable to the parent company was a loss of 173 million RMB, down 86.95% year-on-year [2][3] - **HPV Product Line**: The HPV product line's gross profit decreased by 79.35%, amounting to a reduction of 41.04 million RMB due to centralized procurement policies [2][3][7] AI and Digitalization Progress - **AI Certification**: The company expects to obtain AI Class III certification for its liquid-based cytology (LBC) by Q1 next year, which will enhance its market presence [2][4][6] - **Hospital Trials**: AI and scanning devices have been trialed in over 10 hospitals, but unclear pricing standards have hindered broader adoption [6][24] - **Digital Business**: The digital business includes partnerships for hospital digitalization and product line revenue growth, with specific revenue forecasts for 2025 and 2026 still under development [22] Business Development Areas - **Pathology Co-construction**: This area has seen a revenue increase of approximately 45% year-on-year, reaching 19 million RMB, with 76 co-construction points established [2][8][11] - **Marketing Strategy**: Transitioning from direct sales to distribution has led to the development of nearly 200 new immunohistochemistry clients and 50 new clients for Fisher [13] Future Expectations - **ADP Impact**: The impact of ADP is expected to diminish significantly after Q4 2025, with a positive shift in net profit observed in Q3 [9] - **Market Share Growth**: Following the acquisition of Haoluo Jie, Anbiping anticipates an increase in market share, particularly in major urban hospitals [4][18] - **Sales Performance**: The company aims to maintain or slightly grow its market share, with approximately 6-6.3 million annual outpatient volumes expected [19] Challenges and Competitive Landscape - **Price Pressure**: The company faces price pressures in the immunohistochemistry sector, with over 60 competitors in the market [20] - **Regulatory Environment**: The lengthy application process for AI Class III certification is seen as a challenge, but the company believes its extensive pre-trial data will provide a competitive edge [21] Strategic Goals - **Growth Areas**: Future growth will focus on LBC, immunohistochemistry, and fluorescence in situ hybridization, with plans to leverage AI capabilities [25][26] - **Marketing Initiatives**: The company plans to enhance its market share in high-end hospitals and explore new markets through innovative sales strategies [27] Conclusion Anbiping is navigating a challenging financial landscape with significant declines in revenue and profit, primarily due to centralized procurement policies affecting its HPV product line. However, the company is making strides in AI and digitalization, with a focus on expanding its market share and improving profitability through strategic partnerships and marketing reforms.

Core Viewpoint - Anbipin (688393.SH) reported its Q3 2025 results, highlighting a total institutional ownership of 24.73 million shares, representing 26.43% of the company's total equity, with a slight decline in institutional holding compared to the previous quarter [1] Institutional Ownership - As of October 27, 2025, seven institutional investors disclosed their holdings in Anbipin, with a combined shareholding of 24.73 million shares, accounting for 26.43% of the total share capital [1] - The institutional ownership percentage decreased by 0.56 percentage points compared to the previous quarter [1] Public Fund Disclosure - In this reporting period, 46 public funds were not disclosed compared to the previous quarter, including notable funds such as Bosera Science and Technology Innovation Board Three-Year Open Mixed Fund and Huatai-PineBridge CSI Precision Medical Index (LOF) A [1]

Core Viewpoint - The company, Guangzhou Anbiping Pharmaceutical Technology Co., Ltd., has announced significant changes to its corporate governance structure, including the cancellation of the supervisory board and certain specialized committees of the board, aimed at optimizing management processes and enhancing decision-making efficiency [8][9][10]. Financial Data - The quarterly financial report for the third quarter has not been audited, and the company has provided key financial data and indicators in RMB [3]. - The report indicates that there were no significant non-recurring gains or losses recognized during the reporting period [4]. Corporate Governance Changes - The company has decided to abolish the supervisory board and its rules to streamline governance and improve internal supervision, with responsibilities being integrated into the audit committee of the board [8]. - Several specialized committees of the board, including the strategy committee, nomination committee, and remuneration and assessment committee, have been canceled, with their functions being reassigned to the board and independent directors [9]. - Amendments to the company's articles of association have been proposed to align with the latest legal and regulatory requirements, enhancing governance standards [10].

Core Viewpoint - Anbiping (688393.SH) reported a significant decline in revenue and net profit for the third quarter of 2025 compared to the previous year [1] Financial Performance - The company achieved total operating revenue of 253 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 28.29% [1] - The net profit attributable to shareholders of the parent company was -10.77 million yuan, compared to a net profit of 29.63 million yuan in the same period last year [1] - The basic earnings per share were -0.12 yuan [1]

Group 1 - Company Anbiping (SH 688393) reported a revenue of approximately 253 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 28.29% [1] - The net profit attributable to shareholders of the listed company was a loss of approximately 10.77 million yuan [1] - As of the report date, Anbiping's market capitalization was 2.4 billion yuan [2]

广州安必平医药科技股份有限公司 董事会议事规则 广州安必平医药科技股份有限公司 董事会议事规则 第一章 总则 第一条 为规范广州安必平医药科技股份有限公司（以下简称"公司"）董事 会的议事方式和决策程序，促使董事和董事会有效地履行其职责，提高董事会规范 运作和科学决策水平，根据《中华人民共和国公司法》《中华人民共和国证券法》 《上海证券交易所科创板股票上市规则》等相关法律、法规、规范性文件和《广州 安必平医药科技股份有限公司章程》（以下简称"《公司章程》"）相关规定，制 定本规则。 第二条 董事会是公司经营管理的决策机构，维护公司和全体股东的利益，在《公 司章程》规定和股东会授权范围内，负责公司发展目标和重大经营活动的决策，对 股东会和全体股东负责。 第三条 董事会下设证券事务部，处理董事会日常事务。 第四条 董事会秘书兼任证券事务部负责人，负责公司股东会和董事会会议的筹 备、文件保管以及股东资料管理，办理信息披露、投资者关系管理、处理董事会日 常事务、保管董事会印章等事宜。董事会秘书可以指定证券事务代表等有关人员协 助其处理日常事务。 第二章 董事会的一般规定 第五条 公司设董事会，董事会由九名董事组成，其 ...